Overview

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

Status:
RECRUITING
Trial end date:
2035-07-01
Target enrollment:
Participant gender:
Summary
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
Phase:
PHASE2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
American Cancer Society, Inc.
Treatments:
Aspirin
Ciprofloxacin
Metronidazole